prucalopride
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
379
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
July 09, 2025
OPTIMIZING CAPSULE ENDOSCOPY PATENCY TESTING: A NOVEL PROTOCOL USING GASTROGRAFIN, PRUCALOPRIDE, AND FASTING- A SINGLE CENTER EXPERIENCE
(UEGW 2025)
- No abstract available
Clinical
August 22, 2025
20 years of magnetic particle imaging - from patents to patients.
(PubMed, Biochem Biophys Res Commun)
- "The recent reintroduction of a clinically approved tracer (Resotran) and the emergence of human-scale scanners mark important steps toward clinical implementation. As the field moves forward, the validation of clinical benefit through prospective trials remains a key challenge. Nevertheless, current momentum strongly suggests that MPI is ready to become a valuable tool in clinical diagnostics within the near future."
Journal • Cardiovascular
August 14, 2025
Post-Marketing Study of Prucalopride Safety In Pregnancy
(clinicaltrials.gov)
- P=N/A | N=127 | Active, not recruiting | Sponsor: Takeda | Recruiting ➔ Active, not recruiting | N=616 ➔ 127 | Trial completion date: May 2026 ➔ Feb 2027 | Trial primary completion date: May 2026 ➔ Feb 2027
Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Constipation • Gastroenterology • Gastrointestinal Disorder
July 29, 2025
Current Treatment Options for Children with Functional Constipation-What Is in the Pipeline?
(PubMed, Children (Basel))
- "New agents such as lubiprostone, prucalopride, linaclotide, and plecanatide have demonstrated improved outcomes compared to placebo or conventional therapies, particularly in increasing spontaneous bowel movements. Therapy-resistant FC in children is a complex and impactful condition. An individualized, stepwise approach is essential, with surgical options such as colonic resection reserved as a last resort."
Journal • Review • Constipation • Gastroenterology • Gastrointestinal Disorder • Pediatrics
July 29, 2025
Colon capsule endoscopy today: Brief overview of leading UK and Danish initiatives.
(PubMed, Endosc Int Open)
- "ScotCap pilot reported the highest rate of adequate bowel preparation (79.4%) without using prucalopride...Harmonized quality metrics and shared definitions of success are essential. Efforts should focus on reducing downstream procedures and fostering cross-system learning."
Journal • Review • Colorectal Cancer • Gastrointestinal Disorder • Oncology • Solid Tumor
July 16, 2025
Combinatorial targeting of NMDARs and 5-HT4Rs exerts beneficial effects in a mouse model of Alzheimer's disease.
(PubMed, Alzheimers Res Ther)
- "Our results indicate that combined administration of (R,S)-ketamine + prucalopride is a novel multimodal therapeutic strategy to treat cognitive decline in AD. Future work will further characterize these interactions with the goal of clinical development."
Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Inflammation • Psychiatry • GFAP
July 08, 2025
Prucalopride for Cognitive Functioning in Schizophrenia
(clinicaltrials.gov)
- P=N/A | N=34 | Not yet recruiting | Sponsor: University of Pittsburgh | Trial completion date: Aug 2026 ➔ Dec 2026 | Trial primary completion date: Mar 2026 ➔ Aug 2026
Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia
July 04, 2025
Mechanistic Insights into Prucalopride's Role in IBS Treatment: Schwann-like Enteric Glial Cells as Therapeutic Targets.
(PubMed, Gastroenterology)
- No abstract available
Journal
June 25, 2025
Lupin receives US FDA approval for drug used to treat bowel disorder
(CNBC-TV18)
- "Drugmaker Lupin Ltd. informed the exchanges that it has received approval from the United States Food & Drug Regulator (USFDA) for a drug, which is used in the treatment of Chronic Idiopathic Constipation in adults (CIC). The USFDA has approved Lupin's Prucalopride Tablets, 1 mg, and 2 mg. These tablets are bioequivalent to Motegrity Tablets, 1 mg and 2 mg, of Takeda Pharmaceuticals U.S.A. Inc. According to the IQVIA data dated April 2025, the tablets had an estimated annual sales of $184 million in the US market."
ANDA • Sales • Constipation
May 29, 2025
PROVISIONAL EXPERT RECOMMENDATIONS FOR THE MANAGEMENT OF FECAL INCONTINENCE IN SYSTEMIC SCLEROSIS: A REPORT FROM WORLD SCLERODERMA FOUNDATION (WSF) GASTROINTESTINAL "AD HOC COMMITTEE"
(EULAR 2025)
- "(100%) Consider and prioritize pelvic physical therapy upfront for SSc-FI attributable to pelvic floor weakness before testing, as patients often improve and risk is minimal (if any) (100%) If overflow diarrhea is the issue and slow colonic transit is present, consider a trial of prokinetics (e.g., prucalopride or pyridostigmine). (83.3%) If slow colonic transit is not an issue, consider a trial of other medications (e.g., secretagogues, such as linaclotide, lubiprostone, plecanatide) to help alleviate stool burden... We present provisional recommendations for the evaluation and management of fecal incontinence in SSc. Only minimal refinement and voting is required to finalize these practical recommendations. Our collegiate approach will provide guidance for clinical practice and also inform a future research agenda."
Gastroenterology • Immunology • Rheumatology • Scleroderma • Systemic Sclerosis
March 30, 2025
Provisional expert recommendations for the management of refractory gastroesophageal reflux disease in systemic sclerosis: a report from the World Scleroderma Foundation (WSF) Gastrointestinal "Ad hoc committee"
(EULAR 2025)
- "In patients with refractory GERD and dysphagia, treatment with a promotility agent, such as prucalopride, pyridostigmine, domperidone, or metoclopramide, should be strongly considered as a therapeutic trial (100%)...In the context of refractory GERD and associated nausea, when promotility agents are suboptimal in managing symptoms, consider adding medications with anti-emetic properties (e.g., ondansetron, promethazine, mirtazapine) (85.7%)...Baclofen might be useful for patients with significant reflux episodes, with mainly weakly acidic or non-acidic on pH-impedance studies, and who show positive symptom association (78.6%)... We present provisional recommendations for the management of refractory GERD in SSc. Only minimal refinement and voting is required to finalize these practical recommendations. Our final recommendations shall also include ‘special circumstances’: ILD, myositis and CTD-overlap, and peri-lung transplant."
Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Immunology • Infectious Disease • Myositis • Oncology • Osteoporosis • Pain • Rheumatology • Scleroderma • Systemic Sclerosis • Tobacco Cessation
June 10, 2025
Economic Burden of Patients With Chronic Idiopathic Constipation in the USA Before and After Prucalopride Initiation.
(PubMed, Gastro Hep Adv)
- "Some constipation-related HCRU and health care costs decreased after prucalopride initiation in patients with prior CIC medication use and males. In adults with CIC, constipation-related HCRU and medical costs decreased, while constipation-related health care costs and pharmacy costs increased 6 months after prucalopride initiation."
HEOR • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder
May 17, 2025
Enhanced Intestinal Recovery with Prucalopride Succinate After Gastrectomy: Randomized Clinical Trial
(IGCC 2025)
- "Prucalopride enhances bowel motility and reduces inflammation after gastrectomy, supporting its inclusion in Enhanced Recovery protocols for gastric cancer patients."
Clinical • Gastric Adenocarcinoma • Gastric Cancer • Oncology • Solid Tumor
May 16, 2025
Bowel Blockage Without a Block: Amyloidosis Presenting as Chronic Intestinal Pseudo-Obstruction.
(PubMed, Cureus)
- "His symptoms showed partial improvement with prucalopride, but he continues to require total parenteral nutrition and a venting gastrostomy tube for symptom management. Amyloid subtyping and a bone marrow biopsy are pending to determine the underlying etiology."
Journal • Amyloidosis • Cardiomyopathy • Cardiovascular • CNS Disorders • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Oncology • Pain • Psychiatry • Schizophrenia
March 08, 2025
EFFICACY OF PHARMACOLOGICAL TREATMENT IN PEDIATRIC INTESTINAL PSEUDO-OBSTRUCTION
(DDW 2025)
- "We identified the first instance each patient was treated with erythromycin, amoxicillin/clavulanic acid, prucalopride, pyridostigmine, or octreotide and recorded symptoms before and 1 month after starting the medication. Response to prokinetic medications was variable in our cohort of children with PIPO. While less than half improved with erythromycin, over half had some degree of improvement with prokinetics with a more generalized effect like prucalopride, pyridostigmine, and octreotide. Prospective studies are needed to further investigate this potential difference in prokinetic efficacy."
Clinical • Constipation • Gastroenterology • Gastrointestinal Disorder • Pain • Pediatrics
May 08, 2025
Pharmacokinetics and bioequivalence assessment of two prucalopride formulations in healthy Chinese women: a randomized, open-label, two-period, two-sequence, self-crossover study.
(PubMed, Front Pharmacol)
- "The generic and branded prucalopride tablets were bioequivalent in terms of PK parameters and demonstrated no clinically relevant differences in safety outcomes. http://www.chinadrugtrials.org.cn/clinicaltrials.prosearch.dhtml, identifier CTR20232669."
Journal • PK/PD data
May 01, 2025
Pharmacologic treatment of irritable bowel syndrome. Position statement of the Asociación Mexicana de Gastroenterología, 2024.
(PubMed, Rev Gastroenterol Mex (Engl Ed))
- "Overall, these recommendations provide a solid framework for personalizing treatment, based on the clinical characteristics of the Mexican patient with IBS."
Clinical guideline • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder • Pain
April 30, 2025
Ten-Year Trends in Pharmacologic Management of Gastroesophageal Reflux Disease and Pediatric Feeding Disorders in Young Children.
(PubMed, J Pediatr)
- "In this large, single-center study, prescriptions for young children with GERD or PFD declined over this 10-year period. There were substantial declines in PPI prescribing, contrasting with prior studies. These trends may indicate growing alignment of practice with consensus recommendations that advise against acid suppression as first-line management in this population."
Journal • Gastroenterology • Gastroesophageal Reflux Disease • Pediatrics
April 27, 2025
Pharmacologic Treatment of Irritable Bowel Syndrome with Predominant Constipation
(PubMed, Korean J Gastroenterol)
- "Guanylate cyclase-C agonists (linaclotide and plecanatide) enhance intestinal fluid secretion and motility, normalize bowel movements, and reduce abdominal pain. Na+/H+ exchanger inhibitors (e.g., tenapanor) decrease sodium absorption, increase fluid secretion, and alleviate visceral pain. Lubiprostone activates the chloride channels to facilitate bowel movements, while polyethylene glycol laxatives regulate osmotic pressure to improve stool consistency and ease defecation. Highly selective 5-HT4 agonists, such as prucalopride, accelerate gastrointestinal and colonic transit and improve stool frequency and consistency without increasing the cardiovascular risks raised in earlier agents such as tegaserod...These pharmacology agents have shown efficacy and safety in clinical studies, but drug availability, adverse effects, and variable patient responses are still challenging. Effective strategies to manage IBS-C require a personalized approach, considering the..."
Journal • Review • Cardiovascular • Constipation • Gastroenterology • Gastrointestinal Disorder • Immunology • Pain
April 27, 2025
Chronic, combinatorial targeting of NMDARs and 5-HT4Rs exerts extended behavioral effects against stress-induced perseverative behavior and hyponeophagia.
(PubMed, Neuropsychopharmacology)
- "Here, we evaluated whether administration of combinatorial (R,S)-ketamine, an NMDAR antagonist and Food and Drug Administration (FDA)-approved anesthetic, and prucalopride, a 5-HT type IV receptor (5-HT4R) agonist and FDA-approved drug for chronic idiopathic constipation (CIC), would have additional effects when administered after stress...Our results indicate that chronic administration of K + P has extended benefits for combating stress-induced pathophysiology. Our findings provide strong evidence that future clinical studies using this chronic treatment strategy may prove advantageous in decreasing a broad range of stress-induced psychiatric disorders."
Journal • Anesthesia • CNS Disorders • Constipation • Gastroenterology • Gastrointestinal Disorder • Mental Retardation • Psychiatry
April 16, 2025
Non-Invasive Auricular Acupoint Stimulation Improves Slow-Transit Constipation: Evidence From a Randomized Controlled Trial.
(PubMed, Med Sci Monit)
- "The study group, comprising 30 individuals, received a combination therapy of non-invasive auricular acupoint stimulation and prucalopride, while the control group, also consisting of 30 patients, was administered prucalopride as a monotherapy...Notably, the study cohort demonstrated a more pronounced decrease in neuropeptide Y and nitric oxide concentrations and a more substantial increase in colonic transit capacity and fecal water content compared to the control cohort (P<0.05). CONCLUSIONS Non-invasive auricular acupoint stimulation significantly enhances symptom relief in patients with slow-transit constipation, suggesting its potential as a complementary therapy for constipation management."
Clinical • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder
April 09, 2025
Psychiatric Adverse Effects From Prucalopride in a Medically Complex Adolescent.
(PubMed, Case Rep Pediatr)
- "Clinicians should be aware of this possible side effect, particularly if considering administering prucalopride in patients with neurodevelopmental and psychiatric comorbid histories. Increased supervision and monitoring is recommended in these patients if prucalopride is administrated."
Adverse events • Journal • Constipation • Gastroenterology • Gastrointestinal Disorder • Immunology • Pain • Pediatrics • Psychiatry • Suicidal Ideation
March 19, 2025
Impact of Varying Doses of Prucalopride on Improving Gut Function Recovery After Elective Colorectal Surgery
(clinicaltrials.gov)
- P3 | N=180 | Recruiting | Sponsor: Future University in Egypt | Not yet recruiting ➔ Recruiting
Enrollment open
March 19, 2025
Evolution of the Chicago Classification: Bridging Physiology and Mechanics
(clinicaltrials.gov)
- P=N/A | N=575 | Recruiting | Sponsor: Northwestern University
New trial • Gastrointestinal Disorder • Rare Diseases
March 18, 2025
Prucalopride for Cognitive Functioning in Schizophrenia
(clinicaltrials.gov)
- P=N/A | N=34 | Not yet recruiting | Sponsor: University of Pittsburgh | Trial completion date: Feb 2026 ➔ Aug 2026 | Initiation date: Feb 2025 ➔ Jun 2025 | Trial primary completion date: Dec 2025 ➔ Mar 2026
Trial completion date • Trial initiation date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia
1 to 25
Of
379
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16